000276067 001__ 276067
000276067 005__ 20240229154955.0
000276067 0247_ $$2doi$$a10.3390/ijms24097922
000276067 0247_ $$2pmid$$apmid:37175627
000276067 0247_ $$2pmc$$apmc:PMC10178331
000276067 0247_ $$2ISSN$$a1422-0067
000276067 0247_ $$2ISSN$$a1661-6596
000276067 0247_ $$2altmetric$$aaltmetric:146704941
000276067 037__ $$aDKFZ-2023-00973
000276067 041__ $$aEnglish
000276067 082__ $$a540
000276067 1001_ $$aKasi, Phanindra Babu$$b0
000276067 245__ $$aTheranostics Nanomedicine Applications for Colorectal Cancer and Metastasis: Recent Advances.
000276067 260__ $$aBasel$$bMolecular Diversity Preservation International$$c2023
000276067 3367_ $$2DRIVER$$aarticle
000276067 3367_ $$2DataCite$$aOutput Types/Journal article
000276067 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1692021359_20939$$xReview Article
000276067 3367_ $$2BibTeX$$aARTICLE
000276067 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000276067 3367_ $$00$$2EndNote$$aJournal Article
000276067 500__ $$a#LA:C020#
000276067 520__ $$aColorectal cancer (CRC) is the third most common cancer worldwide, and metastatic CRC is a fatal disease. The CRC-affected tissues show several molecular markers that could be used as a fresh strategy to create newer methods of treating the condition. The liver and the peritoneum are where metastasis occurs most frequently. Once the tumor has metastasized to the liver, peritoneal carcinomatosis is frequently regarded as the disease's final stage. However, nearly 50% of CRC patients with peritoneal carcinomatosis do not have liver metastases. New diagnostic and therapeutic approaches must be developed due to the disease's poor response to present treatment choices in advanced stages and the necessity of an accurate diagnosis in the early stages. Many unique and amazing nanomaterials with promise for both diagnosis and treatment may be found in nanotechnology. Numerous nanomaterials and nanoformulations, including carbon nanotubes, dendrimers, liposomes, silica nanoparticles, gold nanoparticles, metal-organic frameworks, core-shell polymeric nano-formulations, and nano-emulsion systems, among others, can be used for targeted anticancer drug delivery and diagnostic purposes in CRC. Theranostic approaches combined with nanomedicine have been proposed as a revolutionary approach to improve CRC detection and treatment. This review highlights recent studies, potential, and challenges for the development of nanoplatforms for the detection and treatment of CRC.
000276067 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000276067 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000276067 650_7 $$2Other$$acancer therapy
000276067 650_7 $$2Other$$aclinical status
000276067 650_7 $$2Other$$acolorectal cancer
000276067 650_7 $$2Other$$ananomedicine
000276067 650_7 $$2Other$$atheranostics
000276067 650_7 $$2NLM Chemicals$$aNanotubes, Carbon
000276067 650_7 $$07440-57-5$$2NLM Chemicals$$aGold
000276067 650_2 $$2MeSH$$aHumans
000276067 650_2 $$2MeSH$$aNanomedicine: methods
000276067 650_2 $$2MeSH$$aPeritoneal Neoplasms
000276067 650_2 $$2MeSH$$aPrecision Medicine
000276067 650_2 $$2MeSH$$aNanotubes, Carbon
000276067 650_2 $$2MeSH$$aGold
000276067 650_2 $$2MeSH$$aMetal Nanoparticles
000276067 650_2 $$2MeSH$$aNanoparticles: therapeutic use
000276067 650_2 $$2MeSH$$aColorectal Neoplasms: diagnosis
000276067 650_2 $$2MeSH$$aColorectal Neoplasms: drug therapy
000276067 650_2 $$2MeSH$$aTheranostic Nanomedicine
000276067 650_2 $$2MeSH$$aDrug Delivery Systems: methods
000276067 7001_ $$00000-0001-9664-481X$$aMallela, Venkata Ramana$$b1
000276067 7001_ $$00000-0001-6850-780X$$aAmbrozkiewicz, Filip$$b2
000276067 7001_ $$00000-0001-8888-0759$$aTrailin, Andriy$$b3
000276067 7001_ $$aLiška, Václav$$b4
000276067 7001_ $$0P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aHemminki, Kari$$b5$$eLast author$$udkfz
000276067 773__ $$0PERI:(DE-600)2019364-6$$a10.3390/ijms24097922$$gVol. 24, no. 9, p. 7922 -$$n9$$p7922$$tInternational journal of molecular sciences$$v24$$x1422-0067$$y2023
000276067 909CO $$ooai:inrepo02.dkfz.de:276067$$pVDB
000276067 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000276067 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000276067 9141_ $$y2023
000276067 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2022-09-04T08:27:04Z
000276067 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-25
000276067 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-25
000276067 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2022-11-25
000276067 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2022-11-25
000276067 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J MOL SCI : 2022$$d2023-08-25
000276067 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-25
000276067 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-25
000276067 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-25
000276067 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-07-07T16:31:47Z
000276067 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-07-07T16:31:47Z
000276067 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-07-07T16:31:47Z
000276067 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-25
000276067 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-25
000276067 915__ $$0StatID:(DE-HGF)1150$$2StatID$$aDBCoverage$$bCurrent Contents - Physical, Chemical and Earth Sciences$$d2023-08-25
000276067 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-08-25
000276067 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-08-25
000276067 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J MOL SCI : 2022$$d2023-08-25
000276067 9202_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000276067 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000276067 980__ $$ajournal
000276067 980__ $$aVDB
000276067 980__ $$aI:(DE-He78)C020-20160331
000276067 980__ $$aUNRESTRICTED